Memantine Tablet
Product Images NDC 62135-896

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 62135-896). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Memantine HCl Tablets 10mg 60s Label)

Image Description (Memantine HCl Tablets 10mg 60s Label)
Memantine Hydrochloride Tablets USP 10 mg oral tablets, packaged in a bottle label by Chartwell RX, LLC. The label indicates 60 tablets per bottle and is marked Rx Only. It includes storage instructions and a barcode with NDC 62135-896-60.*
FDA Label Image

Image Description (Memantine HCl Tablets 5mg 60s Label)

Image Description (Memantine HCl Tablets 5mg 60s Label)
Label for Memantine Hydrochloride Tablets USP 5 mg oral tablets by Chartwell RX, LLC. The label specifies 60 tablets per bottle, prescription only, and includes storage instructions and patient information website. Contains barcode and lot/revision details.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 1)

Image Description (Memantine HCl Tablets Fig 1)
A line graph showing mean change from baseline in ADCS-ADL score over weeks of treatment up to 28 weeks, comparing Memantine HCl and Placebo groups. The y-axis represents clinical improvement to decline, and the graph indicates a trend of decline in scores over time, with Memantine HCl group showing less decline than Placebo.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 2)

Image Description (Memantine HCl Tablets Fig 2)
A cumulative percentage plot comparing patient outcomes between memantine hydrochloride and placebo groups. The x-axis represents the ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients. Memantine HCl data is marked with open circles, while placebo is marked with filled squares.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 3)

Image Description (Memantine HCl Tablets Fig 3)
A line graph depicting the mean change from baseline in SIB Score over 28 weeks of treatment comparing Memantine HCl and placebo. The x-axis shows weeks of treatment, and the y-axis shows mean change (± SEM) in SIB Score, with indicators for clinical improvement and clinical decline. Two lines represent placebo (decreasing trend) and Memantine HCl (relatively stable).*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 4)

Image Description (Memantine HCl Tablets Fig 4)
A cumulative percentage of patients chart comparing SIB change from baseline between Placebo and Memantine HCl groups. The X-axis represents SIB change values from 15 to -30, and the Y-axis shows cumulative patient percentages from 0 to 100. Memantine HCl shows a higher cumulative percentage of patients with greater SIB changes compared to Placebo.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 5)

Image Description (Memantine HCl Tablets Fig 5)
A line graph showing the mean change from baseline in ADCS-ADL Score over 24 weeks of treatment for two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis represents the mean change with error bars, and the x-axis shows weeks of treatment. The graph includes markers for clinical improvement and clinical decline.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 6)

Image Description (Memantine HCl Tablets Fig 6)
A cumulative percentage of patients graph comparing treatment outcomes with Memantine HCl/Donepezil versus Placebo/Donepezil. The x-axis shows the ADCS-ADL change from baseline, while the y-axis displays the cumulative percentage of patients. Memantine HCl/Donepezil is represented by circles, and Placebo/Donepezil by squares.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 7)

Image Description (Memantine HCl Tablets Fig 7)
A line graph showing mean change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine HCl/Donepezil groups. The y-axis measures mean change with clinical improvement and decline indicated, and the x-axis represents weeks of treatment. Error bars denote variability.*
FDA Label Image

Image Description (Memantine HCl Tablets Fig 8)

Image Description (Memantine HCl Tablets Fig 8)
A cumulative percentage of patients chart plotting SIB (Severe Impairment Battery) change from baseline on the horizontal axis against cumulative percentage on the vertical axis. Two lines represent data for Placebo/Donepezil and Memantine HCl/Donepezil groups, showing comparative shifts in SIB scores.*
FDA Label Image

Image Description (Memantine HCl Tablets Structure)

Image Description (Memantine HCl Tablets Structure)
Chemical structure of memantine hydrochloride showing the arrangement of atoms in the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.